europass

CURRICULUM VITAE DR. VERONICA ZELLI

PERSONAL INFORMATION	**Veronica Zelli** Department of Biotechnological and Applied Clinical Sciences Via Vetoio (Coppito 2), 67100 Coppito (AQ) veronica.zelli@univaq.it

CURRENT POSITION	Fixed-term Research Assistant (RTDa)

EDUCATION OTHER QUALIFICATIONS	**January 2018:** Ph.D. in "Molecular Medicine", Sapienza University of Rome. **March 2017:** RNAseq analysis workshop, Bx2M associazione culturale Bioinformatica per la Medicina Molecolare, Torino. **July 2014:** Second level Degree in "Biomedical Research Applied Biology", Sapienza University of Rome. **December 2011:** First level Degree in "Biological Sciences", Sapienza University of Rome.

ACADEMIC APPOINTMENTS	**August 2019 – present:** Fixed-term Research Assistant (RTDa) at Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila. **February 2018-July 2019:** Research fellow at Department of Molecular Medicine, Sapienza University of Rome. **November 2014-October 2017:** PhD fellow at Department of Molecular Medicine, Sapienza University of Rome. **February 2013-July 2014:** Studentship laboratory training at Department of Molecular Medicine, Sapienza University of Rome.

europass

TEACHING EXPERIENCE	**2019-2020**: - Laboratory course Immunology and General Pathology, CLT Biotechnology; - Seminar courses: Elements of Molecular Diagnostics and Advanced Technologies/Biological databases and their use for molecular analyses. **2021-2021**: - Course Gene Therapy and Molecular Basis of the Diseases, CLM Cellular and Molecular Biotechnology; -Course Updates in General Pathology, CLM Health Professions of Technical Sciences (Diagnostic).
RESEARCH ACTIVITIES	Analysis of the genetic and epigenetic basis of human solid tumors (breast cancer, prostate cancer, melanoma). In particular, • Analysis of DNA methylation levels in genes involved in the pathogenesis of prostate cancer, • Characterization of the molecular profile of *BRCA1/2* positive and negative male breast cancer, • Identification of new diagnostic, prognostic and therapeutic targets in cutaneous melanoma and *BRCA1/2* negative breast cancer cases.
RESPONSIBILITY IN ACADEMIC ACTIVITIES	**2021**: Member of the Communication and Website Commission, Department of Biotechnological and Applied Clinical Sciences. **2020-presente**: Member of the Commission for Student Orientation, Biotechnology Area, Department of Biotechnological and Applied Clinical Sciences.
EDITORIAL BOARD, EDITORIAL ACTIVITIES, SOCIETY MEMBERSHIP	• Member of the Italian cancerology society (SIC) • Member of the European Association for cancer research (EACR)
SCIENTIFIC ACHIEVEMENTS BIBLIOMETRIC INDICATORS	**Scopus Author ID**: 57211727086 **http://orcid.org**: 0000-0002-0047-2919 **H-index**: 7 **Citations:** 164
SELECTED PUBLICATIONS	1. Guadagni S, Farina AR, Cappabianca LA, Sebastiano M, Maccarone R, **Zelli V**, et al. Multidisciplinary Treatment, Including Locoregional Chemotherapy, for Merkel-Polyomavirus-Positive Merkel Cell Carcinomas: Perspectives for Patients Exhibiting Oncogenic Alternative Δ exon 6-7 TrkAIII Splicing of Neurotrophin Receptor Tropomyosin-Related Kinase A. Int J Mol Sci. 2020 Nov 3;21(21):8222. 2. Castelli V, Antonucci I, d'Angelo M, Tessitore A, **Zelli V**, et al. Neuroprotective effects of human amniotic fluid stem cells-derived secretome in an ischemia/reperfusion model. Stem Cells Transl Med. 2020 Oct 7.

3. **Zelli V,** et al. Circulating MicroRNAs as Prognostic and Therapeutic Biomarkers in Breast Cancer Molecular Subtypes. J Pers Med. 2020 Aug 22;10(3):E98. doi: 10.3390/jpm10030098.
4. Farina AR, Cappabianca L, Sebastiano M, **Zelli V**, et al. Hypoxia-induced alternative splicing: the 11th Hallmark of Cancer. J Exp Clin Cancer Res. 2020 Jun 15;39(1):110. doi: 10.1186/s13046-020-01616-9.
5. **Zelli V**, et al. Applications of Next Generation Sequencing to the Analysis of Familial Breast/Ovarian Cancer. High Throughput 2020 Mar; 9(1): 1.
6. Valentini V, **Zelli V**, et al. MiRNAs as potential prognostic biomarkers for metastasis in thin and thick primary cutaneous melanomas. Anticancer Res. 2019 Aug;39(8):4085-4093
7. Rizzolo P, Silvestri V, Valentini V, **Zelli V**, et al. Evaluation of CYP17A1 and CYP1B1 polymorphisms in male breast cancer risk. Endocr Connect. 2019 Jul 1 doi: 10.1530/EC-19-0225.
8. Rizzolo P*, **Zelli V***, et al. Insight into genetic susceptibility to male breast cancer by multigene panel testing: Results from a multicenter study in Italy. International Journal of Cancer 2019 Jan 7. doi: 10.1002/ijc.32106 (*co-first authors).
9. Rizzolo P, Silvestri V, Bucalo A, **Zelli V**, et al. Contribution of MUTYH Variants to Male Breast Cancer Risk: Results From a Multicenter Study in Italy. Frontiers in Oncology 2018. doi: 10.3389/fonc.2018.00583.
10. Santi R, Rizzolo P, Pietragalla M, Valentini V, **Zelli V**, et al. The antiquity of hydrocephalus: the first full palaeo-neuropathological description. Neurol Sci. 2018 Nov 23.
11. Richetta AG, Valentini V, Marraffa F, Paolino G, Rizzolo P, Silvestri V, **Zelli V**,et al. Metastases risk in thin cutaneous melanoma: prognostic value of clinical-pathologic characteristics and mutation profile. Oncotarget. 2018 Aug 14;9(63):32173-32181.
12. Valentini V*, **Zelli V***, et al. PIK3CA c.3140A>G mutation in a patient with suspected Proteus Syndrome: a case report. Clinical Case Reports, 2018. (*co-first authors).
13. Rizzolo P, Silvestri V, Valentini V, **Zelli V**, et al. Gene-specific methylation profiles in BRCA-mutation positive and BRCA-mutation negative male breast cancers. Oncotarget, 2018, Vol. 9, (No. 28), pp: 19783-19792.
14. Zanna I, Silvestri V, Palli D, Magrini A, Rizzolo P, Saieva C, **Zelli V**, et al. Smoking and FGFR2 rs2981582 variant independently modulate male breast cancer survival: A population-based study in Tuscany, Italy. Breast. 2018 Apr 27; 40:85-91.
15. Silvestri V, Rizzolo P, **Zelli V**, et al. A possible role of FANCM mutations in male breast cancer susceptibility: Results from a multicenter study in Italy. The Breast 2018;38: 92-97.
16. Lecarpentier J, Silvestri V, Kuchenbaecker KB, Barrowdale D, Dennis J, McGuffog L, Soucy P, Leslie G, Rizzolo P, Navazio AS, Valentini V, **Zelli V**, et al. Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2. MutationCarriers Using Polygenic Risk Scores. J ClinOncol. 2017 Apr 27:JCO2016694935. doi: 10.1200/JCO.2016.69.4935.

europass

17. Silvestri V, **Zelli V,** et al. Whole Exome Sequencing and targeted gene sequencing provide further insights into the role of *PALB2* as male breast cancer susceptibility gene. Cancer. 2017 Jan 1;123(2):210-218.
18. Rizzolo P, Navazio AS, Silvestri V, Valentini V, **Zelli V,** et al. Somatic alterations of targetable oncogenes are frequently observed in BRCA1/2 mutation negative male breast cancers. Oncotarget. 2016 Nov 8;7(45):74097-74106.
19. Navazio AS, Rizzolo P, Silvestri V, Valentini V, **Zelli V**, et al. EMSY copy numbervariation in male breastcancerscharacterized for BRCA1 and BRCA2 mutations.Breast Cancer Res Treat. 2016 2016 Nov;160(1):181-186.
20. Silvestri V, Rizzolo P, Scarnò M, Chillemi G, Navazio AS, Valentini V, **Zelli V**, et al. Novel and known genetic variants for male breast cancer risk at 8q24.21, 9p21.3, 11q13.3 and 14q24.1: Results from a multicenter study in Italy. Eur J Cancer 2015;51(16):2289-95.

L'Aquila, 25/02/2021